| Name | Title | Contact Details |
|---|
Drummond Advisors provides global consulting services to companies focusing on accounting, tax, legal and business development. Founded in Boston, the consulting firm expanded its presence to the cities of Miami, Orlando, São Paulo and Belo Horizonte as a result of the growth of its customer base with the goal of providing personalized service. The company reunites a multidisciplinary team of professionals with certification, training and experience in Brazilian and North American territory.
Fogo de Chão is a Brazilian chain of churrascarias, or steakhouses, founded in 1979 in Porto Alegre, Brazil. The restaurant specializes in the traditional gaucho method of churrasco, which involves fire-roasting high-quality meats over an open flame. The founders, who grew up in Brazils Serra Gaúcha region, opened their first restaurant to share this culinary heritage. The company expanded to the U.S. in 1997 and has since grown to approximately 76 locations worldwide, including 59 in the U.S. The dining experience at Fogo de Chão features continuous service, where Gaucho chefs carve skewers of freshly grilled meats at the table. The all-you-can-eat menu includes up to 16 types of meats, along with a market table of salads and traditional Brazilian sides. The restaurant promotes a casual dining atmosphere, welcoming guests to enjoy a cultural Brazilian experience without a formal dress code. Fogo de Chão is committed to sourcing and preparing ingredients with respect for food, reflecting its rich culinary traditions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.